Effect of long-term GHRH and somatostatin administration on GH release and body weight in prepubertal female rats.
In order to find a chronic GHRH administration capable of stimulating growth rate without depleting pituitary GH content, prepubertal female rats were subcutaneously (sc) treated with GHRH (1-29)-NH2 and somatostatin (SS). In experiment 1, the rats received sc injections of GHRH and cyclic natural SS for 19 days. In the second study, female rats were continuously treated during 21 days with GHRH, using a slow release pellet, alone or combined with one daily injection of long acting SS (octreotide). In experiment 1, body weight was significantly increased when GHRH was administered at the highest daily dosage (1200 microg/day), accompanied by an slight increment in pituitary GH content. Hypothalamic SS concentrations decreased when GHRH or SS were administered alone whereas the combined treatment with both peptides did not modify this parameter, which suggests the existence of a balance between the chronic actions of both peptides on hypothalamus. In experiment 2, the continuous infusion of GHRH increased plasma GH levels and tended to enhance pituitary GH content. Nevertheless, GHRH effect was not effective enough to increase body weight. By adding one daily injection of SS both GHRH effects on the pituitary gland were abolished. Our study indicates that female rats retain responsiveness to chronic GHRH and SS treatments at both pituitary and hypothalamic levels.
Pérez-Romero
A
A
Departmento de Fisiología, Facultad de Medicina, Universidad Complutense de Madrid, Spain.
Rol de Lama
M A
MA
Ariznavarreta
C
C
Tresguerres
J A
JA
D000818:Animals; D001835:Body Weight / Q000187:drug effects*; D005260:Female; D019382:Human Growth Hormone / Q000097:blood / Q000378:metabolism*; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017337:Sermorelin / Q000008:administration & dosage*; D012741:Sexual Maturation; D013004:Somatostatin / Q000008:administration & dosage* / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects
D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D017337:Sermorelin